aceMachine learning-aided serum N-glycomic signatures reveal potential biomarkers for acute ischemic stroke and minocycline treatment response
The absence of molecular-level tools for diagnosing and monitoring acute ischemic stroke (AIS) underscores the need for novel biomarkers. Serum N-glycosylation represents a promising but remains underexplored source of such markers in AIS. Using hydrophilic interaction liquid chromatography with fluorescence detection (HILIC-FLD), serum N-glycome profiling from healthy controls (HC), AIS patients who had not received prior treatment (AIS) and administered minocycline (A_M) were conducted. A computational pipelin…
A random forest model using six serum glycan features distinguished stroke patients from healthy controls and from minocycline-treated patients, and two features tracked clinical improvement.
The authors describe the two features' value as suggested potential for treatment-response monitoring, and the abstract reports no independent validation cohort.
Evidence
- Peer-reviewedClinica Chimica Acta2026-10-08
How should this claim be treated?
Truvace Impact Record TRV-2026-1688, v1: “Machine learning-aided serum N-glycomic signatures reveal potential biomarkers for acute ischemic stroke and minocycline treatment response.” Truvace, 2026-10-17. /record/TRV-2026-1688 (accessed at citation time). sha256 608a476146b89805…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1688 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.